靶向肝脏血管紧张素原的GalNAc-siRNA治疗高血压的I期临床试验
该I期研究评估了靶向肝脏AGT的GalNAc-siRNA(ART101)在健康志愿者和高血压患者中的安全性、药代动力学和药效学。A部分为双盲安慰剂对照单次递增剂量试验(40例健康成人,25-600 mg),B部分为开放标签单次给药研究(8例高血压患者,600 mg)。药物耐受性良好,未见严重不良事件,血清AGT最大降幅达93%(健康人)和90%(患者),单次600 mg后24周安慰剂校正的24小时动态收缩压降低12.9 mm Hg。
要点
- 单次皮下注射AGT-targeting GalNAc-siRNA耐受性良好,TEAE均为轻中度。
- 健康志愿者中血清AGT最大降幅达93%(600 mg),高血压患者中达90%。
- 单次600 mg后24周,健康参与者安慰剂校正的24小时动态收缩压降低12.9 mm Hg。
核心结论
- 该I期研究未发现严重治疗相关安全信号,观察到持续、剂量依赖的AGT降低和探索性血压下降,支持进一步研究该药作为潜在长效高血压治疗。
研究设计与样本
- I期研究,2025年1月至2026年4月,24周随访,在中国北京友谊医院开展。
- A部分为双盲、安慰剂对照、单次递增剂量试验,40例健康成人按6:2随机接受GalNAc-siRNA(25-600 mg)或安慰剂,39例完成。
- B部分为开放标签、单次给药研究,8例高血压患者接受GalNAc-siRNA 600 mg,全部完成。
主要发现
- A部分活性治疗组30例中23例(76.7%)发生TEAE,安慰剂组10例中7例(70.0%);B部分8例中6例(75.0%)发生TEAE。
- 未观察到严重不良事件、注射部位反应或高钾血症;所有TEAE均为轻中度。
- 血浆暴露(Cmax和AUC)在25 mg至600 mg剂量范围内随剂量增加。
- 健康志愿者中血清AGT平均最大降幅为93%(600 mg时),高血压患者中为90%(600 mg时)。
- 单次600 mg后24周,健康参与者安慰剂校正的24小时动态收缩压降低12.9 mm Hg。
临床怎么用
- 该药为潜在长效高血压治疗,单次给药后AGT降低和血压效应可持续24周。
- 需进一步研究确定其在高血压患者中的疗效和安全性。
局限性
- I期研究样本量小(健康人40例,患者8例),探索性血压评估仅限健康参与者。
- B部分为开放标签设计,无安慰剂对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Angiotensinogen (AGT) is the precursor of angiotensin peptides and a key determinant of renin-angiotensin-aldosterone system activity. ART101 is an investigational N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) designed to durably suppress hepatic AGT synthesis. OBJECTIVE: To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of the AGT-targeting GalNAc-siRNA in healthy volunteers and to provide an initial exploratory assessment of blood pressure effects in patients with hypertension. DESIGN, SETTING, AND PARTICIPANTS: This phase I study was conducted from January 2025 to April 2026 with 24-week follow-up. Part A was a double-blind, placebo-controlled, single ascending-dose trial; part B was an open-label, single-dose study. The study took place at Beijing Friendship Hospital, Capital Medical University, Beijing, China. Part A enrolled 40 healthy adults randomized 6:2 to receive the GalNAc-siRNA (25-600 mg) or placebo; 39 completed the study. Part B enrolled 8 patients with hypertension receiving the GalNAc-siRNA, 600 mg; all completed the study. INTERVENTIONS: A single subcutaneous injection of the AGT-targeting GalNAc-siRNA (25, 75, 150, 300, or 600 mg) or placebo in part A; a single open-label subcutaneous injection of GalNAc-siRNA, 600 mg, in part B. MAIN OUTCOMES AND MEASURES: The primary outcome was safety and tolerability; secondary outcomes included pharmacokinetics, pharmacodynamics, exploratory blood pressure assessments, and renin-angiotensin-aldosterone system biomarkers. RESULTS: Among 40 healthy volunteers (27 [67.5%] male; mean [SD] age, 40.4 [7.8] years) and 8 patients (6 [75.0%] male; mean [SD] age, 47.3 [10.3] years) with hypertension, the AGT-targeting GalNAc-siRNA was well tolerated. In part A, treatment-emergent adverse events (TEAEs) occurred in 23 of 30 active-treatment participants (76.7%) vs 7 of 10 placebo recipients (70.0%); in part B, 6 of 8 patients (75.0%) had TEAEs. No serious adverse events, injection site reactions, or hyperkalemia were observed; all TEAEs were mild to moderate. Plasma exposure (maximum plasma concentration [Cmax] and area under the plasma concentration-time curve [AUC]) increased with dose over the wide dose range from 25 mg to 600 mg. Mean maximum serum AGT reductions of 93% (at 600 mg) in healthy volunteers and 90% (at 600 mg) in patients with hypertension were observed. At 24 weeks after a single 600-mg dose, the placebo-corrected 24-hour ambulatory systolic blood pressure decreased by 12.9 mm Hg in healthy participants. CONCLUSION AND RELEVANCE: In this phase I study, no serious treatment-related safety signals were identified. Sustained, dose-dependent AGT reductions and exploratory blood pressure lowering were observed. These findings support further investigation of the AGT-targeting GalNAc-siRNA as a potential long-acting therapeutic for hypertension. TRIAL REGISTRATION: China Drug Clinical Registry Identifiers: CTR20250041 (part A) and CTR20253973 (part B).
引用
- Zhang J, Wu J, Liu Q, et al. N-Acetylgalactosamine-Conjugated Small Interfering RNA Targeting Hepatic Angiotensinogen in Hypertension: A Phase I Clinical Trial With Randomized Part A and Open-Label Part B. JAMA Cardiol. 2026. PMID: 42961436. doi:10.1001/jamacardio.2026.4936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。